SCHEMBL6071485

SCHEMBL6071485

COc1ccc(C(=O)Nc2ccc3[nH]c4c(ccc5cn[nH]c54)c3c2)cc1OC

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 8/20 0.56
MAOA P21397 3/20 0.54
RAB9A P51151 5/20 0.52
NPC1 O15118 4/20 0.52
NQO2 P16083 1/20 0.52
CASP3 P42574 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
POLB P06746 3/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
PKM P14618 1/20 0.47
KMT2A Q03164 1/20 0.47
MAPT P10636 2/20 0.46
HPSE Q9Y251 1/20 0.46
PLAU P00749 1/20 0.46
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15764659 0.81 NPC1 (0.74) MAOBMAOARAB9ANPC1NQO2
SCHEMBL15875736 0.79 MAOB (0.81) MAOBMAOARAB9ANPC1POLB
SCHEMBL6071066 0.77 MEN1 (0.51) MAOBRAB9ANPC1MEN1KMT2A
SCHEMBL6071196 0.77 KMT2A (0.57) RAB9ANPC1POLBMEN1ALDH1A1
SCHEMBL6071391 0.77 ROCK2 (0.46) RAB9ANPC1MEN1ALDH1A1PKM
SCHEMBL6071553 0.76 ITK (0.51) RAB9ANPC1ALDH1A1MAPTLMNA
SCHEMBL6070762 0.76 MAOB (0.41) MAOBRAB9ANPC1
SCHEMBL6071272 0.76 KDM4E (0.48) MAOBRAB9ANPC1MEN1ALDH1A1
SCHEMBL6071127 0.76 NPC1 (0.51) MAOBRAB9ANPC1POLBALDH1A1
SCHEMBL6071209 0.75 VCP (0.46) MAOBRAB9ANPC1CASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2006-11-23 US disclosed
EP-1599202-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-11-30 EP disclosed
WO-2004071507-A1 TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264493-A1 Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K1, MAP3K19, MAP3K20 MAOB 3302/4885MAOA 3081/4885RAB9A 1100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.